Status:
COMPLETED
Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas
Lead Sponsor:
Turku University Hospital
Conditions:
Low Grade Glioma
Malignant Glioma
Eligibility:
All Genders
18-80 years
Brief Summary
Grading of gliomas is of significant clinical importance since the prognosis as well as the treatment of choice are distinct in low-grade and high-grade gliomas. With standard MRI modalities, however,...
Eligibility Criteria
Inclusion
- Age: 18 to 80 years old
- Language spoken: Finnish or Swedish
- Performance status: Karnofsky score 70 or better or WHO performance status 2 or better
- Supratentorial primary malignant glioma (the diagnosis is based on radiological and clinical grounds)
- Supratentorial recurrent glioma based on MRI and/or \[11C\]methionine PET imaging
- Patient is scheduled to either surgery or stereotactic biopsy
- Mental status: Patients must be able to understand the meaning of the study
- Informed consent: The patient must sign the appropriate Ethical Committee (EC) approved informed consent documents in the presence of the designated staff
Exclusion
- Prior medical history: Patient must have no history of serious cardiovascular, liver or kidney disease
- Any psychiatric condition that compromises the subject's ability to participate in the study
- Infections: Patient must not have an uncontrolled serious infection
- No contraindications for MRI (cardiac pacemaker, intracranial clips etc)
- Patient must not have claustrophobia with serious symptoms
- Pregnant or lactating women
Key Trial Info
Start Date :
March 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT02186262
Start Date
March 1 2014
End Date
December 1 2017
Last Update
June 14 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Turku University Hospital
Turku, Finland, FI-20520